Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:424730.
doi: 10.1155/2013/424730. Epub 2013 Sep 26.

Effects and safety of gyejibongnyeong-hwan on dysmenorrhea caused by blood stagnation: a randomized controlled trial

Jeong-Su Park  1 , Sunju Park, Chun-Hoo Cheon, Seong-Cheon Jo, Han Baek Cho, Eun-Mee Lim, Hyung Ho Lim, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko
Affiliations

Effects and safety of gyejibongnyeong-hwan on dysmenorrhea caused by blood stagnation: a randomized controlled trial

Jeong-Su Park et al. Evid Based Complement Alternat Med. 2013.

Abstract

Objective. This study was a multicenter, randomized, double-blind, and controlled trial with two parallel arms: the GJBNH group and the placebo group. This trial recruited 100 women aging 18 to 35 years with primary dysmenorrhea caused by blood stagnation. The investigational drugs, GJBNH or placebo, were administered for two menstrual periods (8 weeks) to the participants three times per day. The participants were followed up for two menstrual cycles after the administration. Results. The results were analyzed by the intention-to-treat (ITT) dataset and the per-protocol (PP) dataset. In the ITT dataset, the change of the average menstrual pain VAS score in the GJBNH group was statistically significantly lower than that in the control group. Significant difference was not observed in the SF-MPQ score change between the GJBNH group and the placebo group. No significant difference was observed in the PP analyses. In the follow-up phase, the VAS scores of the average menstrual pain and the maximum menstrual pain continually decreased in the placebo group, but they increased in the GJBNH group. Conclusion. GJBNH treatment for eight weeks improved the pain of the dysmenorrhea caused by blood stagnation, but it should be successively administered for more than two menstrual cycles. Trial Registration. This trial is registered with Current Controlled Trials no. ISRCTN30426947.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flowchart.
Figure 2
Figure 2
The trend of the GJBNH group and the control group in the VAS of the average menstrual pain—intention-to-treat (ITT) analysis.
Figure 3
Figure 3
The trend of the GJBNH group and the control group in the VAS of the average menstrual pain—per-protocol (PP) analysis.
See this image and copyright information in PMC

References

    1. Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. British Medical Journal. 2005;332(7550):1134–1138. - PMC - PubMed
    1. Kim HO, Lim SW, Woo HY, Kim KH. Premenstrual syndrome and dysmenorrhea in Korean adolescent girls. Korean Journal of Obstetrics and Gynecology. 2008;51(11):1322–1329.
    1. O’Connell K, Davis AR, Westhoff C. Self-treatment patterns among Adolescent girls with dysmenorrhea. Journal of Pediatric and Adolescent Gynecology. 2006;19(4):285–289. - PubMed
    1. Durain D. Primary dysmenorrhea: assessment and management update. Journal of Midwifery and Women’s Health. 2004;49(6):520–527. - PubMed
    1. Zhu X, Proctor M, Bensoussan A, Smith CA, Wu E. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database of Systematic Reviews. 2007;(4)CD005288 - PubMed

LinkOut - more resources